Cancer Vaccine Partnering Terms and Agreements

294 pages report Published in
Pharmaceuticals
Publisher: Current Partnering

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 160 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms by stage of development.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2009. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of all cancer vaccine partnering deals signed and announced since January 2009.The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2009
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 160 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2009
  • Includes adjuvant and drug delivery deals and alliances since 2009

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Cancer Vaccine Partnering Agreements provides the reader with the following key benefits:

  • In-depth understanding of cancer vaccine deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of cancer vaccine agreements with numerous real life case studies
  • Comprehensive access to over 160 actual cancer vaccine deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of cancer vaccine deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading cancer vaccine deals by value since 2009
  • Identify the most active cancer vaccine dealmakers since 2009
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer vaccine dealmaking
2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Big pharma cancer vaccine dealmaking activity
2.3. Big biotech cancer vaccine dealmaking activity
2.4. Most active in cancer vaccine partnering
2.5. Cancer vaccine partnering by deal type
2.6. Cancer vaccine partnering by stage of development
2.7. Cancer vaccine partnering by cancer indication
2.8. Disclosed deal terms for cancer vaccine partnering
2.8.1 Cancer vaccine partnering headline values
2.8.2 Cancer vaccine deal upfront payments
2.8.3 Cancer vaccine deal milestone payments
2.8.4 Cancer vaccine royalty rates
2.9. The anatomy of cancer vaccine partnering
2.9. The anatomy of a cancer vaccine deal
2.9. a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012
2.9. b. Case study 2: Agenus Bio, NewVac: Dec 19, 2011

Chapter 3 - Leading cancer vaccine deals
3.1. Introduction
3.2. Top cancer vaccine deals by value

Chapter 4 - Cancer vaccine dealmaking directory
4.1. Introduction
4.2. Cancer vaccine deals by company A-Z
4.3. Cancer vaccine deals by stage of development
4.4. Cancer vaccine deals by deal type
4.5. Cancer vaccine deals by oncology therapy area
4.6. Cancer deals by vaccines and adjuvant technology

Chapter 5 - Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
Appendix 1 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Technology Reports

List of Figures

Figure 1: Cancer vaccine partnering since 2009
Figure 2: Big pharma - top 50 - cancer vaccine deals 2009 to 2014
Figure 3: Big pharma cancer vaccine deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - cancer vaccine deals 2009 to 2014
Figure 5: Big biotech cancer vaccine deal frequency - 2009 to 2014
Figure 6: Active cancer vaccine dealmaking activity- 2009 to 2014
Figure 7: Cancer vaccine partnering by deal type since 2009
Figure 8: Cancer vaccine partnering by stage of development since 2009
Figure 9: Cancer vaccine partnering by oncology target since 2009
Figure 10: Cancer vaccine deals with a headline value - by stage of development
Figure 11: Cancer vaccine deal headline value distribution, US$million - discovery stage
Figure 12: Cancer vaccine deal headline value distribution, US$million - preclinical stage
Figure 13: Cancer vaccine deal headline value distribution, US$million - phase I stage
Figure 14: Cancer vaccine deal headline value distribution, US$million - phase II stage
Figure 15: Cancer vaccine deal headline value distribution, US$million - phase III stage
Figure 16: Cancer vaccine deal headline value distribution, US$million - regulatory stage
Figure 17: Cancer vaccine deal headline value distribution, US$million - marketed stage
Figure 18: Cancer vaccine deal headline value - median value by stage of development
Figure 19: Cancer vaccine deals with upfront payment values - by stage of development
Figure 20: Cancer vaccine deal upfront value distribution, US$million - discovery stage
Figure 21: Cancer vaccine deal upfront value distribution, US$million - preclinical stage
Figure 22: Cancer vaccine deal upfront value distribution, US$million - phase I stage
Figure 23: Cancer vaccine deal upfront value distribution, US$million - phase II stage
Figure 24: Cancer vaccine deal upfront value distribution, US$million - phase III stage
Figure 25: Cancer vaccine deal upfront value distribution, US$million - regulatory stage
Figure 26: Cancer vaccine deal upfront value distribution, US$million - marketed stage
Figure 27: Cancer vaccine deal upfront payment value - median value by stage of development
Figure 28: Cancer vaccine deals with milestone payment - by stage of development
Figure 29: Cancer vaccine deal milestone value distribution, US$million - discovery stage
Figure 30: Cancer vaccine deal milestone value distribution, US$million - preclinical stage
Figure 31: Cancer vaccine deal milestone value distribution, US$million - phase I stage
Figure 32: Cancer vaccine deal milestone value distribution, US$million - phase II stage
Figure 33: Cancer vaccine deal milestone value distribution, US$million - phase III stage
Figure 34: Cancer vaccine deal milestone value distribution, US$million - regulatory stage
Figure 35: Cancer vaccine deal milestone value distribution, US$million - marketed stage
Figure 36: Cancer vaccine deals with royalty rates-by stage of development
Figure 37: Cancer vaccine deal royalty rate value distribution, US$million - discovery stage
Figure 38: Cancer vaccine deal royalty rate value distribution, US$million - preclinical stage
Figure 39: Cancer vaccine deal royalty rate value distribution, US$million - phase I stage
Figure 40: Cancer vaccine deal royalty rate value distribution, US$million - phase II stage
Figure 41: Cancer vaccine deal royalty rate value distribution, US$million - phase III stage
Figure 42: Cancer vaccine deal royalty rate value distribution, US$million - regulatory stage
Figure 43: Cancer vaccine deal royalty rate value distribution, US$million - marketed stage
Figure 44: Cancer vaccine deal royalty rate payment value - median value by stage of development
Figure 45: Components of the typical cancer vaccine deal structure
Figure 46: Top cancer vaccine deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Figure 49: Deal type definitions

Related Reports

  • Surgery Partnering 2009-2014
    "Delivery of this report will take 1-3 days after purchase." Surgery Partnering 2009-2014 report provides understanding and access to the surgery partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in surgery partnering deals Top surgery deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Surgery Partnering  2009-2014 provides understanding and access to the surgery partnering deals and agree...
  • Oncology Partnering Terms and Agreements
    "Delivery of this report will take 1-3 days after purchase." The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in oncology partnering deals Average deal terms for headline, upfront and royalty by stage of development Oncology partnering agreement structure Oncology partnering contract documents Top oncology ...
  • Bacterial Partnering Terms and Agreements
    "Delivery of this report will take 1-3 days after purchase." The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in bacterial partnering deals Average deal terms for headline, upfront and royalty by stage of development Bacterial partnering agreement structure Bacterial partnering contract documents Top bact...
  • Orphan Diseases Partnering Terms and Agreements
    " Delivery of this report will take 1-3 days after purchase." The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in orphan diseases partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Orphan diseases partnering contract documents Top orphan diseases deals by value The Orphan...
  • Hematology Partnering Terms and Agreements
    "Delivery of this report will take 1-3 days after purchase." The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in hematology partnering deals Average deal terms for headline, upfront and royalty by stage of development Hematology partnering agreement structure Hematology partnering contract documents Top...